Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sol-Gel Technologies ( (SLGL) ) has provided an update.
On December 17, 2025, Sol-Gel Technologies announced that its Phase 1b study for SGT-210 in Darier Disease did not demonstrate efficacy compared to the vehicle. As a result, the company decided not to continue development for this indication, shifting focus to other small-scale studies for unmet medical needs and prioritizing the Phase 3 program of SGT-610 for Gorlin Syndrome. This decision impacts Sol-Gel’s pipeline by redirecting resources to promising programs, reinforcing its position in rare skin disorder treatments, and shaping expectations for key stakeholders.
The most recent analyst rating on (SLGL) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Sol-Gel Technologies stock, see the SLGL Stock Forecast page.
Spark’s Take on SLGL Stock
According to Spark, TipRanks’ AI Analyst, SLGL is a Neutral.
Sol-Gel Technologies’ stock score reflects significant financial performance challenges due to negative profitability and cash flow issues. Positive technical indicators offer some short-term optimism, but the lack of valuation appeal and guidance from earnings calls creates uncertainty. Strategic financial improvements and clearer future guidance would be needed to enhance the stock’s attractiveness.
To see Spark’s full report on SLGL stock, click here.
More about Sol-Gel Technologies
Sol-Gel Technologies Ltd. is a dermatology-focused pharmaceutical company specializing in developing treatments for skin diseases, including rare and severe disorders. The company has FDA-approved products for acne vulgaris (TWYNEO) and rosacea (EPSOLAY) and is advancing innovative drugs in clinical trials.
Average Trading Volume: 17,320
Technical Sentiment Signal: Buy
Current Market Cap: $117.4M
For an in-depth examination of SLGL stock, go to TipRanks’ Overview page.